Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESLICARBAZEPINE ACETATE

All products: Limited Use (codes 430)

Other products in the same Health Canada class (N03A, N03AF) — coverage varies; not interchangeable

  • Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
  • Oxcarbazepine (Trileptal): not a benefit
  • Rufinamide (Banzel): not a benefit
  • Clonazepam (Rivotril): general benefit
  • Divalproex (Epival): general benefit
  • Ethosuximide (Zarontin): general benefit

14 more in the class list below

Aptiom · DIN 02426870 · 400mg · tablet

Limited Use — Reason for Use code 430 required; Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.Discontinued 2026-06-30 · checked 2026-09-20
StatusLimited Use — Reason for Use code 430 required; Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.
Write on scriptLU code 430 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Aptiom · DIN 02426870 Manufacturer: Sunovion Pharmaceuticals Canada Inc.; listing date 2015-11-26 Health Canada: Cancelled post market since 2026-06-30 · brand APTIOM · ATC N03AF04 ESLICARBAZEPINE · form Tablet · route Oral · ingredients ESLICARBAZEPINE ACETATE 400 MG · company Sumitomo pharma canada, inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $4.9350 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91142 · Verify on the e-Formulary ↗ (DIN 02426870)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02426870). DIN 02426870: Aptiom Raw flags: dinStatus=E, sec12=Y, sec3=Y Item: 281200170; group id 428; item number 1065; lccId 00259; manufacturer id SUO Source form: Tab; strength: 400mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed Source prices (unrounded): $9.8700; ministry $4.9350 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91142
Interchangeable products
Apo-Eslicarbazepine · DIN 02537958 · $4.9350 Auro-Eslicarbazepine · DIN 02527448 · $4.9350
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-06-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

OXCARBAZEPINE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 150mg, 300mg, 600mg · Tab

RUFINAMIDE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 200mg, 400mg · Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Auro-Eslicarbazepine (eslicarbazepine acetate) is indicated as: • Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy (see CLINICAL TRIALS). • Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy. Geriatrics (>65 years of age) There were insufficient numbers of elderly patients who completed partial-onset seizure-controlled trials (N=39) to determine the safety and efficacy of eslicarbazepine acetate in this patient population. Caution should be exercised during dose titration, and age-associated decrease in renal clearance should be considered in elderly patients [see also WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics; ADVERSE REACTIONS, Comparison of Gender, Age and Race, and ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics]. Pediatrics (<18 years of age) The safety and efficacy of eslicarbazepine acetate has not been e… https://pdf.hres.ca/dpd_pm/00080459.PDF PM date: not printed or not captured Source product: AURO-ESLICARBAZEPINE; DIN 02527421; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.